EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against Accelerate Diagnostics - AXDX

The Rosen Law Firm, P.A., a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Accelerate Diagnostics, Inc. (Nasdaq:AXDX) resulting from allegations that Accelerate Diagnostics may have issued materially misleading business information to the investing public.

On February 18, 2015, Seeking Alpha published an article asserting that Accelerate Diagnostics falsely claimed that it had developed a technique for diagnosing pathogens in a blood sample without a need for using a blood culture. In reality, the test required a blood culture, a fact that significantly reduced the value of the technology. On this news, shares of Accelerate Diagnostics fell $4.04 per share or over 18% to close at $18.05 per share on February 20, 2015, damaging investors.

The Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Accelerate Diagnostics investors. If you purchased shares of Accelerate Diagnostics and wish to join the class action and recover your losses, please visit the website at http://www.rosenlegal.com/cases-546.html for more information. You may also contact Phillip Kim or Jonathan Stern of The Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or jstern@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contacts:

The Rosen Law Firm, P.A.
Laurence Rosen, Esq.
Phillip Kim, Esq.
Jonathan Stern
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: 212-686-1060
Toll Free: 866-767-3653
Fax: 212-202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
jstern@rosenlegal.com
www.rosenlegal.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.